P&T
Our
Other
Journal
MediMedia Managed Markets
Managed Care

 

Inhibiting the mTOR Pathway in Trastuzumab-Resistant, HER-2-Positive Advanced Breast Cancer Patients: BOLERO-3, Phase 3

Inhibiting the mTOR Pathway in Trastuzumab-Resistant, HER-2-Positive Advanced Breast Cancer Patients: BOLERO-3, Phase 3

Ruth O’Regan, MD, says that the combination of everolimus plus vinorelbine and trastuzumab may be considered an appropriate option in trastuzumab-resistant, HER-2-positive advanced breast cancer (BOLERO-3, Phase 3).